Novel seleno-hydantoin palladium(II) complex - antimigratory, cytotoxic and prooxidative potential on human colon HCT-116 and breast MDA-MB-231 cancer cells.
Selenium and palladium containing compounds separately exert multifunctional effects on cells. While selenium containing compounds usually exert antioxidative properties, palladium(II) containing compounds are cytotoxic and prooxidative. Here we investigated biological effects of bicyclic seleno-hydantoin cis-7a-ethyl-5-methyl-5-phenylselanylmethyl-tetrahydro-pyrrolo[1,2-c]imidazole-1,3-dione (Hid-Se), and its palladium(II) complex, trans-bis-(cis-7a-ethyl-5-methyl-5-phenylselanylmethyl-tetrahydro-pyrrolo[1,2-c]imidazole-1,3-dionato) palladium(II) chloride ((Hid-Se)2Pd) on human colon HCT-116 and breast MDA-MB-231 cancer cell lines. Hid-Se and (Hid-Se)2Pd showed prooxidative and cytotoxic character. In all performed experiments (Hid-Se)2Pd proved to be more active, i.e. this substance exerted greater prooxidative effect, cytotoxicity and influence on cell migration potential. Even though Hid-Se and (Hid-Se)2Pd enhanced migration of HCT-116 cells, very important feature of these substances is the strong antimigratory potential on metastatic MDA-MB-231 cells.
Department of Biology and Ecology, Faculty of Science, University of Kragujevac, Radoja Domanovića 12, 34000 Kragujevac, Serbia. zivanovicm@kg.ac.rs.
Marko N
MN
Živanović
Jelena V
JV
Košarić
Biljana
B
Šmit
Dragana S
DS
Šeklić
Radoslav Z
RZ
Pavlović
Snežana D
SD
Marković
D000970:Antineoplastic Agents / Q000008:administration & dosage; D002465:Cell Movement / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004339:Drug Compounding / Q000379:methods; D045325:HCT116 Cells; D006801:Humans; D006827:Hydantoins / Q000737:chemistry; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D016877:Oxidants / Q000008:administration & dosage; D010165:Palladium / Q000008:administration & dosage* / Q000737:chemistry; D017382:Reactive Oxygen Species / Q000378:metabolism; D012643:Selenium / Q000008:administration & dosage* / Q000737:chemistry; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D006827:Hydantoins; D016877:Oxidants; D017382:Reactive Oxygen Species; D010165:Palladium; D012643:Selenium